Determine the necessary mass, volume, or concentration for preparing a solution.
Activity Type | Activity Value -log(M) | Mechanism of Action | Activity Reference | Publications (PubMed IDs) |
---|
SKU | Size | Availability | Price | Qty |
---|---|---|---|---|
B288291-5mg | 5mg | In stock | $147.90 | |
B288291-10mg | 10mg | In stock | $246.90 | |
B288291-25mg | 25mg | In stock | $494.90 | |
B288291-50mg | 50mg | In stock | $791.90 | |
B288291-100mg | 100mg | In stock | $1,425.90 |
Selective inhibitor of integrin α2β1
Specifications & Purity | Moligand™, ≥98%(HPLC) |
---|---|
Biochemical and Physiological Mechanisms | Selective inhibitor of integrinα2β1(EC50= 130 nM forα2β1binding to collagen I). Binds to theα2I domain. Exhibits selectivity forα2β1over integrinsα3β1,α4β1,α5β1andαv. Inhibits platelet aggregation to collagen I coated capillaries under flow. Also inhibits |
Storage Temp | Store at -20°C |
Shipped In | Ice chest + Ice pads |
Grade | Moligand™ |
Action Type | INHIBITOR |
Mechanism of action | Inhibitor of integrin α2β1 |
Product Description | Product description BTT-3033 is an orally active conformation-selective inhibitor of α2β1 (EC50: 130 nM) by binding to the α2I domain. BTT-3033 inhibits platelet binding to collagen Ⅰ and cell proliferation, and induces cell apoptosis. BTT-3033 can be used in the research of prostate cancer, inflammation and cardiovascular disease. |
Activity Type | Activity Value -log(M) | Mechanism of Action | Activity Reference | Publications (PubMed IDs) |
---|
Activity Type | Activity Value -log(M) | Mechanism of Action | Activity Reference | Publications (PubMed IDs) |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Mechanism of Action | Action Type | target ID | Target Name | Target Type | Target Organism | Binding Site Name | References |
---|
IUPAC Name | 1-[4-[[1-(4-fluorophenyl)pyrazol-4-yl]sulfonyl-methylamino]phenyl]-3-phenylurea |
---|---|
INCHI | InChI=1S/C23H20FN5O3S/c1-28(33(31,32)22-15-25-29(16-22)21-11-7-17(24)8-12-21)20-13-9-19(10-14-20)27-23(30)26-18-5-3-2-4-6-18/h2-16H,1H3,(H2,26,27,30) |
InChi Key | NSLIQOPYDUKWTA-UHFFFAOYSA-N |
Canonical SMILES | CN(C1=CC=C(C=C1)NC(=O)NC2=CC=CC=C2)S(=O)(=O)C3=CN(N=C3)C4=CC=C(C=C4)F |
Isomeric SMILES | CN(C1=CC=C(C=C1)NC(=O)NC2=CC=CC=C2)S(=O)(=O)C3=CN(N=C3)C4=CC=C(C=C4)F |
PubChem CID | 49841251 |
Molecular Weight | 465.5 |
Enter Lot Number to search for COA:
Find and download the COA for your product by matching the lot number on the packaging.
Lot Number | Certificate Type | Date | Item |
---|---|---|---|
F23141009 | Certificate of Analysis | May 30, 2023 | B288291 |
F23141010 | Certificate of Analysis | May 30, 2023 | B288291 |
F23141024 | Certificate of Analysis | May 30, 2023 | B288291 |
F23141026 | Certificate of Analysis | May 30, 2023 | B288291 |
F23141085 | Certificate of Analysis | May 30, 2023 | B288291 |
F23141119 | Certificate of Analysis | May 30, 2023 | B288291 |
F2314885 | Certificate of Analysis | May 30, 2023 | B288291 |
F2314931 | Certificate of Analysis | May 30, 2023 | B288291 |
F2314987 | Certificate of Analysis | May 30, 2023 | B288291 |
F2314989 | Certificate of Analysis | May 30, 2023 | B288291 |
Solubility | Solvent:DMSO, Max Conc. mg/mL: 46.55, Max Conc. mM: 100 |
---|
1. Nissinen L, Koivunen J, Käpylä J, Salmela M, Nieminen J, Jokinen J, Sipilä K, Pihlavisto M, Pentikäinen OT, Marjamäki A et al.. (2012) Novel α2β1 integrin inhibitors reveal that integrin binding to collagen under shear stress conditions does not require receptor preactivation.. J Biol Chem, 287 (53): (44694-702). [PMID:23132859] [10.1021/op500134e] |